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Abstract
Purpose
The aim of this registry study was to analyze the long-term safety and effectiveness of
recombinant human growth hormone (rhGH) in South Korean pediatric patients (�2 years
of age) with growth hormone deficiency GHD) of idiopathic or organic etiology, idiopathic
short stature, Turner syndrome, small for gestational age and chronic renal failure.
Methods
The study patients were followed-up till two years after the epiphyseal closure, with visits
scheduled every six months. The outcome measures included the incidence of adverse
events (AEs, in particular, neoplasia, glucose intolerance and hypothyroidism), as well as
height standard deviation score (Ht SDS) and annual height velocity. The results of the
interim analysis of a 5-year accumulated data for 2,024 patients (7,342 patient-years, PY)
are presented.
Results
A total of 14 neoplasms were diagnosed (191/100,000 PY); 7 out of 9 malignancies were
recurrent craniopharyngioma found in patients with organic GHD. Seven cases of glucose
intolerance (95/100,000 PY) and 22 cases of hypothyroidism (300/100,000 PY) were
detected; about half of the cases (4 and 10 cases each) were considered to be related with
rhGH treatment. Most of the growth-retarded patients showed continuous improvement in
Ht SDS, with the most prominent effect observed within a year of treatment initiation. The
beneficial effect of rhGH on Ht SDS gain was maintained for 2–4 years.
PLOS ONE | https://doi.org/10.1371/journal.pone.0216927 May 16, 2019 1 / 18
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Rhie Y-J, Yoo J-H, Choi J-H, Chae H-W,
Kim JH, Chung S, et al. (2019) Long-term safety
and effectiveness of growth hormone therapy in
Korean children with growth disorders: 5-year
results of LG Growth Study. PLoS ONE 14(5):
e0216927. https://doi.org/10.1371/journal.
pone.0216927
Editor: Aamir Ahmad, University of South Alabama
Mitchell Cancer Institute, UNITED STATES
Received: October 26, 2018
Accepted: April 24, 2019
Published: May 16, 2019
Copyright: © 2019 Rhie et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Raw data of this
paper can be found in the following address:
https://doi.org/10.5061/dryad.3d01n50.
Funding: This cohort study was sponsored by LG
Chem, Ltd (http://www.lgchem.com/global/main).
LG Chem, Ltd provided support in the form of
salary for author EYK and involved with the study
design, interpretation of data, decision to publish,
and preparation of the manuscript. The specific
Conclusions
The incidence of AEs of interest in rhGH-treated patients was low, and most of the neo-
plasms were benign and/or non-related to rhGH. Most patients benefited from the therapy in
terms of height increment.
Introduction
Nowadays, indications for treatment with recombinant human growth hormone (rhGH)
include not only growth hormone deficiency (GHD) but also a number of other conditions,
such as Turner syndrome (TS), Prader-Willi syndrome (PWS), small for gestational age
(SGA), chronic renal failure (CRF) and idiopathic short stature (ISS) [1–5]. Although rhGH
therapy is generally considered to be safe, still there are safety issues that need to be addressed,
i.e., the risk of neoplasia and cardiovascular mortality [6–8]. Another important question is
the long-term effectiveness of rhGH in various indications. This subject is rarely explored in
clinical trials conducted for a purpose of product registration, which usually have relatively
short follow-up periods.
To overcome these knowledge gaps, several large-scale registry studies of rhGH-treated
patients have been initiated [9–11]. In addition, pharmaceutical companies carried out
research on the safety and effectiveness of their products in various populations [12–15]. How-
ever, the efficacy and safety of rhGH have not been investigated in a large number of Asian
patients. Thus, we designed a registry study (LG Growth Study, LGS) to analyze the long-term
safety and effectiveness of rhGH (Eutropin inj., Eutropin AQ inj., Eutropin Pen inj. and Eutro-
pin Plus inj., LG Chem, Ltd., Korea) in patients with GHD, ISS, TS, SGA and CRF. Detailed
descriptions of the individual rhGH products and study background are provided in the previ-
ous publication introducing the study protocol and cohort characteristics [16]. In this paper,
we present the results of the interim analysis of a 5-year accumulated data from the LGS.
Methods
Patients and study design
LGS is a multi-center (total 73 sites), non-interventional registry study to evaluate the long-
term safety and effectiveness of four rhGH products: a weekly rhGH (Eutropin Plus inj.) and
three daily rhGHs (Eutropin inj., Eutropin AQ inj. and Eutropin Pen inj.) in patients�2 years
of age with GHD, ISS, TS, SGA, or CRF. Patients treated with one of the aforementioned prod-
ucts were prospectively followed-up till two years after the epiphyseal closure. If patients who
had been already on treatment were registered, the preregistration data were collected retro-
spectively. A set of minimal eligibility criteria was applied for each indication to register eligi-
ble patients, and approved product leaflets were referenced for choosing the initial dosage of
rhGH [16]. When GH stimulation test was indicated, the investigator chose the appropriate
test(s) among commonly used methods in the clinic, such as insulin tolerance test, L-dopa test,
clonidine test, or glucagon test. No interventional element was applied under the study proto-
col. All treatment-related decisions were left at an investigator’s discretion to collect the data
from real-life clinical practice.
Measurements of height, bone age, insulin-like growth factor I (IGF-I), IGF binding protein
3 (IGFBP-3), thyroid stimulating hormone (TSH), total thyroxine (T4), free T4 (fT4), hemo-
globin A1c (HbA1c) and serum glucose levels were recorded at 6-month intervals. No central
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laboratory was used; all laboratory analyses were carried out according to local standard proce-
dures of each site. IGF-1 SDS and IGFBP-3 SDS were calculated based on normative data for
Korean population [17]. Adverse events (AEs), including AEs of interest (such as neoplasia,
glucose intolerance and hypothyroidism), were collected through interviews and/or chart
reviews. To maintain the real-life setting, all decisions regarding choice of rhGH product, its
dosage and titration were solely at the investigator’s discretion, whereas the methodology of
data collection was standardized to guarantee the integrity of the results. The study was con-
ducted in accordance with the principles expressed in the Declaration of Helsinki and applica-
ble regulations. The study protocol and consent form were reviewed by the institutional
review board of each medical center, when required, and the list of institutional review boards
that approved the study is provided in S1 Table. Written informed consent was obtained from
the patients and/or their parents/legal representatives. The study was registered at Clinical-
Trials.gov (identifier: NCT01604395).
Statistical analysis
All patients treated at least once with one of the target products were included in the safety
analysis. The incidence of AEs was expressed per 100,000 patient-years (PY). To calculate total
PY, each patient’s time was summed up from the first date of rhGH treatment to the earliest
date of the last follow-up, withdrawal, death or data cut-off. AEs were coded using MedDRA
software ver. 17.0 (International Federation of Pharmaceutical Manufacturers Associations,
http://www.meddra.org). Adverse drug reactions (ADRs) were classified as AEs with definite,
probable, possible or unassessable causative relationship with rhGH.
Patients who did not satisfy the indication criteria, received rhGH for off-label treatment or
had incomplete information for baseline or post-treatment height measurements were
excluded from the effectiveness analysis. Height standard deviation score (Ht SDS) and annual
height velocity (HV) were calculated from height records at protocol defined timepoints
(with ± 1-month window period). To calculate Ht SDS, the following equation was used
referencing the Box-Cox transformation (L), median (M), and coefficient of variation (S) val-
ues from growth standard for Korean children and adolescents [18]: height SDS = [Power
(measured height/M, L)– 1] / L×S.
The data cut-off point was 22 March 2017. The study data and the results of the interim
analysis were evaluated by the dedicated Observational Study Monitoring Board. The results
for CRF cohort (n = 9) were included in the whole dataset, but are not presented separately in
the effectiveness aspect due to a small sample size. Missing data were not substituted. Results
with the P-values <0.05 were considered statistically significant. All statistical analyses were
performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA).
Results
Patients characteristics
A total of 2,277 patients were registered between November 2011 and March 2017. The safety
data were available for 2,024 patients, which corresponds to 7,342 PY. Other 253 patients were
excluded from the safety analysis because of missing treatment record or indication informa-
tion, lack of consent or registration error (Fig 1). Median age at the time of registration was
8.49 years (range 2.01 to 19.23 years); 82.9% (male: 89.9%, female: 78.5%) patients were prepu-
bertal (Tanner stage I). Other baseline characteristics are presented in Table 1. The most com-
mon indication for rhGH treatment was GHD (64.1%); the vast majority of GHD patients had
idiopathic GHD (IGHD) (n = 1,189, 91.7%). Median Ht SDS in the study population was
-2.26. Median Ht SDS at the baseline was the lowest in TS cohort (-2.58), and the most severe
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bone age (BA) delay (BA–chronological age) was observed in GHD cohort (median -1.71
years).
Out of 2,024 patients included in the safety set, 1,046 were excluded from the effectiveness
analysis because of non-eligibility for indications, missing baseline or follow-up data, off-label
use and non-adherence (Fig 1). Demographic characteristics of the remaining 978 patients
Fig 1. Disposition of patients.
https://doi.org/10.1371/journal.pone.0216927.g001
Table 1. Baseline demographic characteristics of patients.
Variable Total
(n = 2,024)
GHD
(n = 1,297)
TS
(n = 197)
SGA
(n = 206)
ISS
(n = 315)
CRF
(n = 9)
Sex:
male 1048
(51.8%)
771
(59.4%)
0
(0.0%)
104
(50.5%)
167
(53.0%)
6
(66.7%)
female 976
(48.2%)
526
(40.6%)
197
(100.0%)
102
(49.5%)
148
(47.0%)
3
(33.3%)
Age (years) 8.49
(2.01, 19.23)
8.42
(2.10, 19.23)
9.24
(2.01, 18.58)
6.66
(3.04, 14.18)
9.05
(2.38, 16.10)
8.58
(2.48, 15.88)
Pubertya
pre-pubertal 793
(82.9%)
502
(87.3%)
107
(83.0%)
77
(83.7%)
105
(66.0%)
2
(100.0%)
pubertal 164
(17.1%)
73
(12.7%)
22
(17.1%)
15
(16.3%)
54
(34.0%)
0
(0.0%)
BA (years) 6.8
(0.6, 17)
6.0
(0.6, 17)
8.5
(1.0, 14)
5.5
(1.5, 13.5)
8.4
(2.0, 15.6)
8.8
(1.5, 13.5)
BA-CA (years) -1.46
(-8.83, 4.49)
-1.71
(-8.83, 2.71)
-0.87
(-5.75, 2.53)
-1.05
(-4.67, 2.51)
-0.98
(-5.30, 4.49)
-1.69
(-4.87, 0.30)
Height SDS -2.26
(-6.97, 6.23)
-2.25
(-6.97, 6.23)
-2.58
(-6.34, -0.66)
-2.23
(-5.14, -0.18)
-2.17
(-5.31, 1.54)
-2.43
(-3.54, 0.00)
BMI SDS -0.27
(-16.88, 3.47)
-0.23
(-16.88, 2.88)
0.51
(-1.92, 3.47)
-0.81
(-5.60, 2.09)
-0.58
(-4.60, 2.69)
-0.89
(-2.89, 1.61)
a Some patients’ puberty data are missing and only available data are accounted.
Data show numbers (%) or medians (min, max).
BA bone age, BMI body mass index, CA chronological age, CRF chronic renal failure, GHD growth hormone deficiency, ISS idiopathic short stature, SDS standard
deviation score, SGA small for gestational age, TS Turner syndrome.
https://doi.org/10.1371/journal.pone.0216927.t001
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included in the effectiveness set resembled those of the safety set (S2 Table). The upper quartile
for Ht SDS was -2.07, which implies that >75% of patients were severely growth-retarded.
Use of rhGH products
Approximately 80% of the study patients were initially treated with a daily rhGH (n = 1,626,
Eutropin inj. or Eutropin AQ inj.) whereas others were treated with a weekly rhGH (n = 398,
Eutropin Plus inj.). Median (IQR) on-treatment follow-up period was 3.03 years (1.67, 4.65):
2.87 years (1.56, 4.51) for Eutropin inj., 2.29 years (0.9, 4.02) for Eutropin Plus inj. and 0.89
years (0.51, 1.52) for Eutropin AQ inj.. No significant changes were noted in the yearly
descriptive statistics for rhGH doses in each indication. The 5-year overall median (IQR) dose
of Eutropin inj. for GHD, TS, SGA, ISS and CRF cohorts was 0.24 mg/kg/week (0.21, 0.27),
0.31 mg/kg/week (0.27, 0.33), 0.27 mg/kg/week (0.22, 0.31), 0.26 mg/kg/week (0.21, 0.29) and
0.29 mg/kg/week (0.25, 0.31), respectively. Median (IQR) dose of Eutropin Plus inj. for GHD
cohort was 0.60 mg/kg/week (0.53, 0.73). Statistical characteristics of rhGH dose for the effec-
tiveness set were similar. Median (IQR) on-treatment follow-up period for the effectiveness set
was 3.60 years (2.08, 5.10): 3.71 years (2.35, 5.14), 2.32 years (1.27, 3.82), 4.84 years (3.53, 7.08)
and 1.99 years (1.44, 2.59) years for GHD, ISS, TS and SGA cohorts, respectively.
Adverse events during on-treatment follow-up period
During on-treatment follow-up period (6,898 PY), 954 AEs (13,831 per 100,000 PY) were
reported in 458 patients (22.6%). Proportions of patients experiencing AEs, ADRs, SAEs, and
serious ADRs are provided in the Table 2. The following results are based on the number of
events (cases). Most AEs (97.7%) were mild (772 cases) or moderate (160 cases) in severity,
and 80.4% resolved. The most frequent AEs were upper respiratory tract infections (1,305 per
100,000 PY), typically unrelated to rhGH treatment. Out of 954 AEs, 119 (12.5%) were ADRs
(1,725 per 100,000 PY). The most common type of ADRs were reactions in the injection site
(25 cases, 362 per 100,000 PY), and among them, injection site pain (13 cases, 188 per 100,000
PY). Other common ADRs were headache (15 cases, 217 per 100,000 PY), hypothyroidism (10
cases, 145 per 100,000 PY) and arthralgia (7 cases, 101 per 100,000 PY). The highest incidence
of AEs (per 100,000 PY) was documented in ISS cohort (18,745), followed by TS (17,885), SGA
(15,179) and GHD (11,796) cohorts, and the highest incidence of ADRs (per 100,000 PY) in
ISS cohort (2,734), followed by SGA (2,039), GHD (1,605) and TS (1,346) cohorts. Approxi-
mately 10% of AEs (94 cases) were serious AEs (SAEs), and 8 of them (116 per 100,000 PY)
were regarded as rhGH-related, autoimmune thyroiditis, hypothyroidism, diabetes mellitus,
hematuria, intervertebral disc protrusion, supraventricular tachycardia (1 case each) and cra-
niopharyngioma (2 cases). No mortality was reported during the on-treatment follow-up
period.
Adverse events during off-treatment follow-up period
Off-treatment follow-up has been completed or ongoing in 335 patients. Median off-treatment
follow-up duration was 1.0 year (range 0 to 9.55 years). During this period, 26 additional AEs
(25 non-related to rhGH and 1 ADR) occurred including 5 SAEs. One SAE (craniopharyn-
gioma recurrence) was evaluated as rhGH-related. A 12-year-old male patient from IGHD
cohort, with unremarkable medical history, was diagnosed with medulloblastoma during the
rhGH treatment (approximately one year after the start of the rhGH treatment). At the base-
line, the patient’s IGF-I (SDS) and IGFBP-3 (SDS) were 161 ng/mL (-0.84) and 5,280 ng/mL
(3.83), respectively, and the initial dosage was 0.28 mg/kg/week with Eutropin inj. About 6
months later, IGF-I (SDS) and IGFBP-3 (SDS) were 257 ng/mL (-0.51) and 3,291 ng/mL
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(0.40), respectively. The treatment was discontinued immediately after the diagnosis of medul-
loblastoma. Approximately 1.2 years later, death of the patient was confirmed during the off-
treatment follow-up process.
Adverse events of interest
The incidence of AEs of interest was analyzed for the whole study period. Fourteen neoplasms
(191 per 100,000 PY) were diagnosed in 11 patients (6 females, 5 males): 5 benign (68 per
100,000 PY) and 9 malignant (123 per 100,000 PY) (Table 3). Seven cases out of total 9 malig-
nant neoplasms were recurrence cases in craniopharyngioma, diagnosed solely in OGHD
patients, 2–6 years after the diagnosis of primary tumors and 8 months to 5 years after rhGH
treatment initiation. Four neoplasms, three malignant and one benign, were considered as
ADRs (Table 4). Ovarian dysgerminoma was reported in 9 years old TS (45,X/46,XY) patient
during the rhGH treatment (approximately one year after the start of the rhGH treatment).
The treatment was discontinued immediately after the diagnosis and she recovered after
receiving chemotherapy.
Hypothyroidism (22 cases, 300 per 100,000 PY) was reported primarily in TS (11 cases) and
GHD cohorts (9 cases; 6 patients with IGHD and 3 with OGHD), typically during treatment
(21 cases) and mostly in female patients (19 cases). Median time elapsed from GH treatment
onset -to hypothyroidism diagnosis was 1.9 (IQR: 0.8, 2.7) years. More than 50% of the cases
were considered to be unrelated to rhGH, and 10 (136 per 100,000 PY) were considered as
ADRs.
Table 2. Incidence of adverse events during on-treatment follow-up and whole study period.
Variable Total
(n = 2,024)a
IGHD
(n = 1,189)
OGHD
(n = 107)
TS
(n = 197)
SGA
(n = 206)
ISS
(n = 315)
CRF
(n = 9)
On-treatment follow-up period:
AEs 458
(22.6%)
231
(19.4%)
45
(42.1%)
72
(36.6%)
35
(17.0%)
70
(22.2%)
5
(55.6%)
ADRs 93
(4.6%)
43
(3.6%)
13
(12.2%)
11
(5.6%)
8
(3.9%)
17
(5.4%)
1
(11.1%)
SAEs 66
(3.3%)
31
(2.6%)
12
(11.2%)
13
(6.6%)
4
(1.9%)
6
(1.9%)
-
Serious ADRs 7
(0.4%)
4
(0.3%)
2
(1.9%)
1
(0.5%)
- - -
Whole study period:
AEs 462
(22.8%)
232
(19.5%)
46
(43.0%)
73
(37.1%)
35
(17.0%)
70
(22.2%)
6
(66.7%)
ADRs 94
(4.6%)
43
(3.6%)
14
(13.1%)
11
(5.6%)
8
(3.9%)
17
(5.4%)
1
(11.1%)
SAEs 68
(3.4%)
31
(2.6%)
13
(12.2%)
13
(6.6%)
4
(1.9%)
6
(1.9%)
1
(11.1%)
Serious ADRs
�
8
(0.4%)
4
(0.3%)
3
(2.8%)
1
(0.5%)
- -
a Addition of each subgroup number does not sum up to 2,024 as one patient with GHD could not be classified as either IGHD or OGHD. The patient with non-
specified GHD etiology did not experience any adverse event. Data show numbers (%) of patients with events.
�
Total of nine serious ADRs were reported in eight patients during whole study period: autoimmune thyroiditis, hypothyroidism, diabetes mellitus, hematuria,
intervertebral disc protrusion and supraventricular tachycardia (n = 1 each) and craniopharyngioma recurrence (n = 3). Except one case of craniopharyngioma
recurrence, all occurred during on-treatment follow-up period.
ADR adverse drug reaction, AE adverse event, CRF chronic renal failure, GHD growth hormone deficiency, IGHD idiopathic growth hormone deficiency, ISS idiopathic
short stature, OGHD organic growth hormone deficiency, SAE serious AE, SGA small for gestational age, TS Turner syndrome.
https://doi.org/10.1371/journal.pone.0216927.t002
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There were seven cases (95 per 100,000 PY) of glucose intolerance (Table 3). Of these, four
cases were regarded as ADRs, including type 2 diabetes mellitus (T2DM, 2 cases), glucose tol-
erance impaired (1 case), and hyperglycemia (1 case). In case of new-onset T2DM, three cases
were detected during the whole follow-up period (Table 5). In 3 out of 7 glucose intolerance
cases, hyperglycemia (2 cases) and glucose tolerance impaired (1 case), have been resolved.
Scoliosis (11 cases, 150 per 100,000 PY) was reported in SGA (1 case), TS (2 cases) and
GHD cohorts (8 cases; 7 patients with IGHD and 1 with OGHD) during treatment. Median
time elapsed from GH treatment onset -to scoliosis diagnosis was 2.3 (IQR: 1.1, 3.2) years. Five
cases (68 per 100,000 PY) were considered as ADRs.
Laboratory results
Irrespective of the cohort, IGF-I SDS and IGFBP-3 SDS significantly increased at six months
after rhGH treatment (p<0.001), and their levels remained at a plateau thereafter (Fig 2).
Supraphysiological levels of IGF-I (IGF-I SDS>+2) were found at least once in 508 patients
(25.1%), more frequently within one year of treatment and in TS cohort (82/197 patients; Fig
3). Median IGF-I to IGFBP-3 ratio remained at a stable level of 0.1. The subgroup with at least
one IGF-I SDS value >+2 did not differ from the other patients in terms of AE (15,027 vs.
29,197 per 100,000 PY) and SAE frequencies (1,940 vs. 2,527 per 100,000 PY), but more often
presented with serious ADRs (226 vs. 181 per 100,000 PY).
Other laboratory findings included a slight decrease in TSH levels, observed until 42
months of treatment. No significant changes were found in fT4 and HbA1c levels (Fig 2).
Effectiveness results
Median (IQR) height SDS for patients included in the effectiveness set was -2.37 (-2.89, -2.07,
n = 976) at the baseline, and -1.39 (-2.05, -0.87, n = 243) and -1.30 (-1.99, -0.62, n = 148) at 36
Table 3. Incidence of adverse events of interest during whole study period.
Variable Total
(n = 2,024)a
IGHD (n = 1,189) OGHD (n = 107) TS
(n = 197)
SGA
(n = 206)
ISS
(n = 315)
CRF
(n = 9)
Death 1 (14) 1 (23) - - - - -
All neoplasms 14 (191) 4 (93) 7 (1289) 3 (255) - - -
Malignancy 9 (123) 1 (23) 7 (1289) 1 (85) - - -
Benign 5 (68) 3 (70) 2 (170) - - -
Hypothyroidism 22 (300) 6 (140) 3 (552) 11 (937) - 1 (118) 1†
Glucose intolerance
�
7 (95) 2 (47) 3 (552) - 1 (218) 1 (118) -
Scoliosis 11 (150) 7 (163) 1 (184) 2 (170) 1 (218) - -
Benign intracranial hypertension 1 (14) 1 (23) - - - - -
Pancreatitis 1 (14) 1 (23) - - - - -
Fluid retention 1 (14) 1 (23) - - - - -
Gynecomastia 1 (14) - - - - 1 (118) -
Sleep apnea syndrome 1 (14) 1 (23) - - - - -
a Addition of each subgroup number does not sum up to 2,024 as one patient with GHD could not be classified as either IGHD or OGHD. The patient with non-
specified GHD etiology did not experience any adverse event. Data show absolute numbers (rates per 100,000 patient-years).
�
Includes diabetes mellitus (n = 3), hyperglycemia (n = 3) and glucose tolerance impaired (n = 1),
†Due to small sample size, rates per 100,000 patient-years of chronic renal failure cohort was not analyzed separately.
CRF chronic renal failure, GHD growth hormone deficiency, IGHD idiopathic growth hormone deficiency, ISS idiopathic short stature, OGHD organic growth
hormone deficiency, SGA small for gestational age, TS Turner syndrome.
https://doi.org/10.1371/journal.pone.0216927.t003
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and 48 months of treatment, respectively. Ht SDS at six months of treatment was significantly
higher (p<0.001) than at the baseline in GHD, ISS, TS and SGA cohorts. In GHD cohort, an
increase in height SDS continued until the fourth year, and in the other cohorts, until the sec-
ond year (Fig 4). After 4 years of GH treatment, mean changes (95% CI) in Ht SDS in GHD
(n = 95), TS (n = 44) and SGA cohorts (n = 5) were 1.52 (1.32, 1.73), 0.86 (0.64, 1.08) and 1.27
Table 4. Neoplasms reported during whole study period.
Indication for
rhGH treatment
Sex Age at the
baseline (years)
Age at neoplasm
diagnosis (years)
Neoplasm type rhGH at the time
of diagnosis
Relationship with
rhGH
Action
undertaken
Outcome
Malignant
Organic GHD female 19 21 craniopharyngioma
recurrence
� ,†
yes possible rhGH stopped ongoing
Organic GHD male 9 14 craniopharyngioma
recurrence†
yes unlikely rhGH
interrupted
resolved
17 craniopharyngioma
recurrence†,‡
yes unlikely none resolved
Organic GHD female 13 14 craniopharyngioma
recurrence
� ,†
yes possible rhGH stopped resolved
15 craniopharyngioma
recurrence†
yes unlikely none resolved
17 craniopharyngioma
recurrence†,§
off-treatment unlikely none resolved
Organic GHD male 7 8 craniopharyngioma
recurrence
� ,†
off-treatment possible rhGH stopped resolved
Idiopathic GHD male 12 13 medulloblastoma† yes unlikely rhGH stopped death
TS female 8 9 ovarian dysgerminoma
stage unspecified†
yes not related rhGH
interrupted
resolved
Benign
Idiopathic GHD female 9 9 skin papilloma
�
yes possible none resolved
Idiopathic GHD male 6 8 skin papilloma yes unlikely none resolved
Idiopathic GHD male 3 11 skin papilloma yes not related none resolved
TS female 4 11 neurofibroma yes not related none ongoing
TS female 10 13 osteochondroma yes not related none ongoing
�
Evaluated as related to rhGH treatment,
†reported as SAE,
‡Epilepsy was reported as AE approximately 2 years after this was resolved (ongoing).
§CSF leak was reported as AE 6 days after this was resolved (resolved after 9 days).
GHD growth hormone deficiency, rhGH recombinant human growth hormone, TS Turner syndrome
https://doi.org/10.1371/journal.pone.0216927.t004
Table 5. New-onset diabetes cases reported during whole study period.
Type of
DM
Indication for
rhGH treatment
Age at the
baseline
(years)
Age at DM
diagnosis (years)
Additional risk
factors
BMI (SDS) at
the baseline
rhGH at the
time of
diagnosis
Relationship
with rhGH
Action
undertaken
Outcome
Type 2 Idiopathic GHD 9 11 Family history
(+)
1.98 yes possible none ongoing
Type 2 Organic GHD 16 17 - 2.27 yes not related none ongoing
Type 2 Organic GHD 11 15 - 1.47 yes probable rhGH
interrupted
ongoing
DM Diabetes mellitus, BMI body mass index, GHD growth hormone deficiency, rhGH recombinant human growth hormone
https://doi.org/10.1371/journal.pone.0216927.t005
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Fig 2. Laboratory tests for IGF-I, IGFBP-3, HbA1c, TSH, and free T4 (safety set). The symbols represent median values and the vertical bars indicate
interquartile range.
https://doi.org/10.1371/journal.pone.0216927.g002
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Fig 3. IGF-I SDS. (A) and IGF-I to IGFBP-3 ratio (B) in a subgroup of patients with supra-physiological level of IGF-I. The
boxes represent interquartile ranges and the whiskers represent 10th and 90th percentiles. (A) In the subgroup of patients
having supra-physiological level of IGF-I, some were observed to have extremely high SD scores of IGF-I since the initiation
of rhGH treatment; however, such extreme values tended to disappear as treatment progressed. (B) IGF-I to IGFBP-3 ratio
stayed relatively stable since 6 months of treatment.
https://doi.org/10.1371/journal.pone.0216927.g003
Fig 4. Auxological measurements through the fourth year. The symbols indicate the median values and the vertical bars indicate
interquartile range. IGHD was confirmed by at least two GH stimulation tests (peak responses from both tests<10 ng/mL).
https://doi.org/10.1371/journal.pone.0216927.g004
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(0.53, 2.00), respectively. In GHD subgroups, mean Ht SDS gain (95% CI) at 4 years was 1.68
(1.49, 1.87) in IGHD (n = 71) and 1.06 (0.48, 1.64) in OGHD (n = 24).
At six months of treatment, mean (95% CI) HV was 9.20 (9.02, 9.38), being nearly twice as
high as at the baseline. Most patients achieved the highest HV during the first year of treatment
(Fig 4). At 12 months, the highest HV was documented in ISS cohort (mean: 8.81, 95% CI:
8.31, 9.32) and the lowest in TS cohort (mean: 7.27; 95% CI: 6.94, 7.60). In GHD, SGA and ISS
cohorts, mean HV was maintained above 7 cm per year until the second year and then
decreased gradually, down to 5.30–5.74 cm annually at four years. Irrespective of the study
timepoint, HV for TS cohort was lower than for other cohorts (Fig 4).
Discussion
According to a general consensus, rhGH can be safely administered for patients without
known risk factors of malignant neoplasia, but the available evidence in this matter is still
inconclusive. Recently, SAGhE study demonstrated a higher incidence of bone and bladder
neoplasms in the rhGH-treated cohort, but without enough evidence for a causal role of the
agent [19]. In our study, 9 malignant neoplasms were diagnosed in 6 patients (crude incidence:
0.3%, 123 per 100,000 PY). After excluding seven cases of craniopharyngioma recurrence, pri-
mary malignant neoplasia incidence was 0.1% (27 per 100,000 PY); in the investigators’ causal-
ity assessment, none were rhGH-related. The incidence of malignant neoplasms was slightly
higher than in the previous studies, KIGS and NCGS (16.4 and 5.8 per 100,000 PY, respec-
tively) [20,21]. However, the latter two studies were markedly larger than LGS (58,603 and
33,161 patients participated in KIGS and NCGS, respectively). Furthermore, it should be
emphasized that the neoplasia risk in rhGH-treated patients is known to decrease with follow-
up time, and both KIGS and NCGS were based on more than 20-year accumulated data, as
compared with only a 5-year dataset in our study. Hence, conclusions about cancer risk in the
South Korean pediatric population treated with rhGH should not be formulated earlier than at
the end of the designated follow-up period for all targeted patients.
One patient died during off-treatment follow-up period after being diagnosed with medul-
loblastoma (mortality: 0.05%, 14 per 100,000 PY). A contribution of rhGH therapy was consid-
ered unlikely in this case. Medulloblastoma is one of the most common pediatric cancers [22],
and previous studies found no correlation between rhGH treatment and progression or recur-
rence of brain tumors [6,23,24].
The incidence of AEs associated with glucose intolerance in LGS patients was 0.3% (95 per
100,000 PY), and T2DM was diagnosed in 0.15% of the study participants. While the risk of
glucose intolerance and T2DM in rhGH-treated patients with GHD and ISS is low, those who
were treated with rhGH for TS or SGA are more prone to metabolic diseases than individuals
from the general population [6,25]. However, it is unclear whether the increased metabolic
risk in this group is directly related to the treatment, or is rather a consequence of underlying
conditions. In a previous study, 199 SGA patients treated with rhGH were followed-up for 5
years; both insulin resistance and beta cell dysfunction caused by rhGH have been resolved
within 6 months post-treatment, and at the end of the follow-up period, body composition,
insulin sensitivity and beta-cell function did not differ between the study group and the
untreated controls [26]. This implies that metabolic AEs related to rhGH treatment are revers-
ible and probably clinically irrelevant.
Our cohort included 22 patients who developed hypothyroidism during rhGH treatment
(incidence: 1.1%, 300 per 100,000 PY). Most patients who developed hypothyroidism received
rhGH due to TS (n = 11) or GHD (n = 9). Hypothyroidism is a common comorbidity in TS
patients, occurring regardless of rhGH treatment [27]; indeed, in 8 out of 11 patients with TS
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included in LGS study, the investigators evaluated hypothyroidism as not related to rhGH
therapy.
Scoliosis has been observed in 11 patients (incidence: 0.5%, 150 per 100,000 PY). Among
them, two were patients with TS, in which condition scoliosis is known to be more prevalent
even without rhGH treatment [6,28]. As the rapid growth during rhGH treatment may accel-
erate the progression of scoliosis, regular radiographic check-up is recommended for those
receiving rhGH therapy [1,6].
One of the concerns related to administration of rhGH at higher doses is potential risk asso-
ciated with the supraphysiological level of IGF-I. In our study, 25% of patients at least once
had IGF-I SDS >+2, which corresponds to the supraphysiological level of this compound.
However, in most of these patients, the elevated levels of IGF-I were observed temporarily,
usually at early stages of the treatment, and then remained within the recommended range.
Although serious ADR rate in patients with IGF-I SDS >+2 was slightly higher than in those
with lower IGF-I SDS values, none of them was withdrawn from the study prematurely. The
increase in IGF-I SDS was associated with a concomitant increase in IGFBP-3 SDS and there-
fore, IGF-I to IGFBP-3 ratio remained at a relatively stable level. Thus, it may be presumed
that the increase in IGF-I level was counterbalanced by IGFBP-3. The increase in IGF-I level is
generally known to be proportional to rhGH dose. The TS cohort, in which median dose of
rhGH was the highest, contained also the largest proportion of patients with IGF-I SDS>+2.
In International Outcome Study, including 13,843 patients receiving Norditropin, no signifi-
cant correlation was found between the rhGH dose and AE rate [29], which is consistent with
our findings.
While the treatment outcomes were most favorable in patients with complete GHD, indi-
viduals with TS seemed not to benefit fully from rhGH therapy. In up to 61% of patients for TS
cohort, Ht SDS at one-year follow-up was no greater than 0.5. A previous study demonstrated
that the outcomes of rhGH treatment are predicted by its dose, age at the therapy onset, mid-
parental height and growth response within the first year [30]. The 5-year overall median dose
of rhGH in our TS cohort was 0.31 mg/kg/week; this shows more than a half of the patients
received rhGH at a slightly lower dose than recommended (0.33 mg/kg/week). Another poten-
tial reason for less satisfactory growth outcomes in TS patients might be their relatively older
age at treatment initiation (median 9.49 years). Although no strict guideline exists in this mat-
ter, it is generally accepted that the earlier the rhGH treatment implemented, the better its
outcome.
More than 50% of patients considered in the safety set were excluded from the effectiveness
analysis. The largest proportion of the excluded patients did not satisfy the indication require-
ments, especially for IGHD (25.8%) and ISS (55.9%). This implies that regardless of the reim-
bursement policies and commonly accepted clinical guidelines, there might be a parental
pressure to prescribe rhGH products; indeed, such a tendency was documented in one study
conducted in the South Korean population [31]. The rationale for the implementation of
rhGH treatment in all ISS patients raises controversies and hence, the decision to start the
therapy in this group should be based on comprehensive evaluation of several factors, among
them quality of life-related issues, economic burden and functional impact, rather than solely
on height benefit and parental request [32].
The results presented above may have a few limitations inherent to each registry study. This
study is an observational study without an untreated control group. Moreover, laboratory
parameters, such as IGF-I and IGFBP-3, were measured at each site, which might contribute
to an interlaboratory measurement bias. To overcome these limitations and to minimize the
risk of bias due to missing data, we used a systematic approach to data collection. Many regis-
try studies are based on voluntary reporting of AEs, and/or only ADRs are registered.
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Meanwhile, our patients were seen at participating centers every six months, to collect all AE
data and physical measurements in a standardized manner.
Conclusions
The spectrum of AEs present in rhGH-treated Korean patients was similar to previously
reported for other populations. The incidence of AEs, including adverse events of interest,
such as neoplasia, glucose intolerance and hypothyroidism, was low. No alarming safety signal
was identified at the time of the interim analysis. Most of the growth-retarded patients showed
continuous improvement in their Ht SDS during the follow-up period, with the most promi-
nent effect observed within a year of treatment initiation. The beneficial effect of rhGH on Ht
SDS gain was maintained for up to four years.
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